World Journal of Personalized Medicine

Editor-in-Chief

Ivan I. Dedov, MD, PhD, Professor
the vice-president of the Russian academy of Sciences, main specialist of the Ministry of health of Russian Federation in endocrinology, president of the Russian association of endocrinologists, director of Endocrinology research centre (Moscow)

Publication model

Medical Open Access electronic-only journal

Peer-review type: open post-publication peer-review process (see details).

Publication scedule: articles are published as soon as they are ready.

Aims and research fields of the journal

The peer-reviewed medical journal “World Journal of Personalized Medicine” aims to publish the highest quality articles in the field of personalized medicine.

The journal publishes review papers, original articles, case reports, and letters to the editor.

The journal provides a forum for exchange of ideas between basic and clinical scientists as well as medical professionals, healthcare organizations, and patients who seek the best strategies for integrating personalized medicine into clinical practice.

The journal covers all aspects of personalized medicine. Key areas include:

  • Basic and Clinical Immunology
  • Bioinformatics
  • Biomarker studies
  • Cell, Molecular, and Stem Cell biology
  • Cytogenetics, Genomics, Proteomics, and Metabolomics
  • Drug discovery and delivery
  • Molecular Endocrinology
  • Epigenetics
  • Ethical, legal, and social issues in personalized medicine
  • Molecular diagnostics
  • Neuroscience
  • Nutrigenomics
  • Oncology
  • Orthomolecular medicine
  • Pathology
  • Pharmacogenomic
  • Preemptive medicine (Personalized prevention)
  • Regenerative medicine
  • System biology

Current Issue

Vol 2, No 1 (2018)

Case report
Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23 gene in child from Russia
Kulikova K.S., Vasiliev E.V., Petrov V.M., Tiulpakov A.N.

Abstract

Autosomal dominant hypophosphatemic rickets (ADHR) is a rare disorder characterized of renal phosphate wasting and rickets/osteomalacia. ADHR is caused by mutations in a circulating peptide, fibroblast growth factor 23 (FGF23). The clinical manifestations depend on the age of patients and the importance of hypophosphatemia. In childhood, clinical manifestations are rickets with lower extremity deformities. In adult onset, it can cause osteomalacia, osteoporosis, bone pain, tiredness. ADHR displays incomplete penetrance and variability in age of onset of clinical features. Biochemical and hormonal markers of the disease are hypophosphatemia, hyperphosphaturia, increased alkaline phosphatase level and a normal level of 1,25(OH) 2D. We present the first report a baby with ADHR from Russia which one was found heterozygous for the R179Q mutation in FGF23 gene.

World Journal of Personalized Medicine. 2018;2(1):5-9
views

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies